Myriad Genetics (MYGN)
NASDAQ:MYGN
Want to see MYGN full AI Analyst Report?
MYGN Stock Chart & Stats
$5.08
$0.24(1.68%)
At close: 4:00 PM EST
$5.08
$0.24(1.68%)
Day’s Range― - ―
52-Week Range$3.53 - $8.59
Previous CloseN/A
Volume154.82K
Average Volume (3M)1.73M
Market Cap
$512.85M
Enterprise Value$500.78M
Total Cash (Recent Filing)$124.40M
Total Debt (Recent Filing)$211.50M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Jul 30, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.30
Shares Outstanding94,448,210
10 Day Avg. Volume1,332,938
30 Day Avg. Volume1,734,763
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.56
Price to Sales (P/S)0.70
P/FCF Ratio-41.58
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue0.60
Enterprise Value/Gross Profit0.86
Enterprise Value/Ebitda-1.50
Forecast
1Y Price Target
$7.50Price Target Upside47.64% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)0.06
Revenue Forecast (FY)$863.46M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 69–71% indicate durable pricing power and favorable test mix. Strong gross profitability provides structural capacity to fund R&D, commercial launches and working capital even while operating leverage and profitability recover, supporting long-term margin sustainability.
Re-accelerated Revenue Growth In Core TestsMeaningful top-line momentum in hereditary testing and GeneSight reflects expanding clinical adoption and market-share gains across core franchises. Durable volume and ASP improvements tied to clinician adoption and reimbursement gains support multi-quarter revenue growth potential as launches scale.
Depth Of Pipeline And Launch InvestmentsA multi-product pipeline (MRD, Prolaris+AI, FirstGene) plus earmarked capital and commercial hires creates multiple structural levers for future revenue diversification. Planned investment and available capital materially increase the odds of successful commercialization and sustained long-term growth if execution holds.
Bears Say
Persistent Losses And Negative FCFLarge, persistent net losses and negative free cash flow indicate the business still consumes capital despite improving revenue. This erodes equity, increases reliance on financing, and reduces financial flexibility to sustain higher commercial spend if revenue ramps slower than planned.
Prenatal Segment WeaknessA 15% YoY decline in prenatal revenues driven by lost accounts signals structural vulnerability in a significant segment. Operational disruptions that caused account loss may take multiple quarters to recover and reduce revenue diversification, increasing dependence on oncology franchises.
Execution & Reimbursement Risk For MRD And Sales RampCommercial execution and payer coverage are key for MRD and new product payoffs. Slow sales ramp and uncertain reimbursement timelines create durable execution risk: planned back-half acceleration depends on multi-quarter hiring productivity and broad payer adoption, which may lag assumptions.
Myriad Genetics News
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $3.53 and its highest was $8.59 in the past 12 months.
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is $512.85M.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Jul 30, 2026 which is in 33 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on May 05, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.068 by -$0.022.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Monthly dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -0.06.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 94,448,210 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.068. Following the earnings report the stock price went down -18.29%.
Which hedge fund is a major shareholder of Myriad Genetics?
Currently, no hedge funds are holding shares in MYGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myriad Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.50 (47.64% Upside)
$7.50 (47.64% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 453.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $27.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.05%
12-Months-Change
Fundamentals
Return on Equity
-109.09%
Trailing 12-Months
Asset Growth
-33.04%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
MYGN Company Deck
MYGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful progress in core growth engines (double-digit hereditary cancer growth, robust GeneSight performance, solid gross margins and a deep product pipeline) and management reaffirmed full-year guidance and positive adjusted EBITDA expectations. Near-term pressures include a Q1 adjusted EBITDA loss, higher operating expense due to accelerated commercial hiring, and a notable prenatal revenue decline. Management is investing to drive back-half acceleration but execution (sales ramp, MRD adoption, payer reimbursement) will determine pace of recovery. On balance, the positives around market share gains, product launches and revenue guidance outweigh the short-term profitability and prenatal headwinds.View all MYGN earnings summariesMYGN Stock 12 Month Forecast
Average Price Target
$7.50
▲(47.64% Upside)
Technical Analysis
Ownership Overview
5.46% Insiders
16.65% Mutual Funds
4.84% Other Institutional Investors
56.65% Public Companies and
Individual Investors